Histogenics Update: Agreement with Japan PMDA on NeoCart Regulatory Path

Histogenics  successfully completed consultations with Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the regulatory path for NeoCart® autologous cell therapy for the treatment of knee cartilage defects. Histogenics has nearly completed enrollment in a 245-patient Phase III clinical trial conducted under a Special Protocol...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us